Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma

References

• American Cancer Society [Internet]. Treating B-cell non-Hodgkin lymphoma; [cited 2017 Mar 20]. Available from: http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-treating-b-cell-lymphoma
   Google Scholar
• Ebrahim AS, Sabbagh H, Liddane A, et al. Hematologic malignancies: newer strategies to counter the BCL-2 protein. J Cancer Res Clin Oncol. 2016;142:2013–2022.
   PubMed Web of Science ®Google Scholar
• Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647–656.
   PubMed Web of Science ®Google Scholar
• Venclexta (venetoclax) [US prescribing information]. North Chicago (IL): AbbVie Inc; 2016.
   Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106–1117.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826–833.
   PubMed Web of Science ®Google Scholar
• Freise KJ, Jones AK, Verdugo ME, et al. Moving beyond maximum tolerated dose for targeted oncology drugs: use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients. Clin Pharmacol Ther. Forthcoming. [cited 2017 Apr 17]. DOI: 10.1002/cpt.712
   Web of Science ®Google Scholar
• Wei A, Strickland SA, Roboz GJ, et al. Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged ≥65 years with acute myeloid leukemia. Blood. 2016;128:102.
   Web of Science ®Google Scholar
• Salem AH, Agarwal SK, Dunbar M, et al. Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol. 2016;56:1355–1361.
   PubMed Web of Science ®Google Scholar
• Salem AH, Agarwal SK, Dunbar M, et al. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol. 2017;57:484–492.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Salem AH, Danilov AV, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017;83:846–854.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Hu B, Chien D, et al. Evaluation of rifampin’s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol. 2016;56:1335–1343.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, DiNardo CD, Potluri J, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39:359–367.
   PubMed Web of Science ®Google Scholar
• Freise KJ, Shebley M, Salem AH. Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model. J Clin Pharmacol. 2017;57:796–804.
   PubMed Web of Science ®Google Scholar
• Salem AH, Hu B, Freise KJ, et al. Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers. Clin Drug Investig. 2017;37:303–309.
   PubMed Web of Science ®Google Scholar
• Salem AH, Dunbar M, Agarwal SK. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anti-Cancer Drugs. Forthcoming. [cited 2017 May 30]. DOI: 10.1097/CAD.0000000000000522
   Web of Science ®Google Scholar
• Freise KJ, Jones AK, Eckert D, et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Pharmacokinet. 2017;56:515–523.
   PubMed Web of Science ®Google Scholar
• Freise KJ, Dunbar M, Jones AK, et al. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemother Pharmacol. 2016;78:847–853.
   PubMed Web of Science ®Google Scholar
• Freise KJ, Jones AK, Menon R, et al. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol. Forthcoming. [cited 2016 Dec 16]. DOI: 10.1002/hon.2373
   Web of Science ®Google Scholar
• Jones AK, Freise KJ, Agarwal S, et al. Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and Non-Hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016;18:1192–1202.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. JCO. 2009;27:120–126.
   PubMed Web of Science ®Google Scholar
• R Core Team [Internet]. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2014. Available from: http://www.R-project.org/
   Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. JCO. 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research [Internet]. Clinical pharmacology and biopharmaceutics review for ibrutinib. Application Number 205552Orig1s000; [cited 2017 Mar 20]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000ClinPharmR.pdf
   Google Scholar
• Freise KJ, Jones AK, Eckert D, et al. Relationship of venetoclax dose and exposure to response in relapsed or refractory chronic lymphocytic leukemia and non-Hodgkin's lymphoma subjects. Cancer Res. 2016;76:2045.
   Web of Science ®Google Scholar
• Mandrekar SJ, Sargent DJ. All-comers versus enrichment design strategy in phase II trials. J Thorac Oncol. 2011;6:658–660.
   PubMed Web of Science ®Google Scholar
• Del Gaizo Moore V, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117:112–121.
   PubMed Web of Science ®Google Scholar
• Egle A, Harris AW, Bouillet P, et al. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA. 2004;101:6164–6169.
   PubMed Web of Science ®Google Scholar